Formulation and Drug Delivery

Velesco Pharma Acquires New R&D and cGMP Analytical Lab

November 01, 2018

Pharmaceutical Technology's In the Lab eNewsletter

he acquisition expands the company’s formulation and analytical R&D services.

Biogen and Samsung Bioepis Launch Humira Biosimilar in Europe

October 30, 2018

The companies announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).

Mylan Launches Humira Biosimilar in Europe

October 30, 2018

Mylan announced the launch of its biosimilar to AbbVie’s Humira across major European markets.

FDA Promotes Complex Generics and Combination Products

October 19, 2018

To achieve a more dynamic marketplace, FDA is issuingguidance documents and targeted advisories to support R&D on complex generics and combination products.

Amgen Launches Adalimumab Biosimilar in Europe

October 17, 2018

Amgen’s biosimilar to AbbVie’s Humira (adalimumab) is the first inflammation biosimilar from Amgen's portfolio to launch in Europe.

Cambrex Development Center in North Carolina Focuses on Continuous Flow

October 17, 2018

Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy.

Dow Expands Capacity for Polyethlene Glycols

October 15, 2018

The company’s planned investment in its alkoxylation facility in the United States Gulf Coast will also expand production capacity for its polyethylene glycols.

MilliporeSigma Offers Insect Platform for Viral Vaccines and Gene Therapy Development

October 15, 2018

The company will collaborate with GlycoBac to offer an insect cell line for the development of viral vaccines and gene therapies.

Sandoz Humira Biosimilar Patent Dispute Resolved

October 12, 2018

Novartis’ Sandoz has reached a global patent resolution for Hyrimoz (adalimumab), its biosimilar to AbbVie’s Humira (adalimumab).

Scientists Develop New Vaccine for Lassa Fever and Rabies

October 12, 2018

A new investigational vaccine, LASSARAB, shows promise for use against Lassa fever and rabies.